The oral administration of GELNs can promote intestinal stem cell proliferation and organoid formation, stimulates Wnt/β-catenin pathway activation, and enhances the expression of stem cell growth-related genes. Lgr5-EGFP-IRES-CreERT2 mice were effectively prevented from DSS-induced colitis at a daily dose of 2 mg. This evidence concerns the gene LGR5 and colitis.